drugset / Trial / NCT01935167

To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy

NCT01935167

Phase 2 Completed 158 enrolled Dong Wha Pharmaceutical Co. Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

Phase 2 clinical study to evaluate of the efficacy and safety of DW1029M on microalbuminuria in Patients With Diabetic Nephropathy

Timeline

Start
2013-10
Primary completion
2014-08
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject DW1029M Unknown 600 mg
Subject DW1029M Unknown 1200 mg